Potential risk for medication error between ZALTRAP® (aflibercept, formulated for intravenous use) and EYLEA® (aflibercept, formulated for intravitreal use)

Sanofi-Aventis Singapore Pte Ltd would like to alert healthcare professionals to the potential risk of medication error between Zaltrap® and Eylea®.Both products contain the active ingredient, aflibercept, but Zaltrap® is formulated for intravenous use only while Eylea® is formulated for intravitreal use only. Zaltrap® must only be administered through intravenous injection (after dilution) and ophthalmic or intravitreal use is contraindicated due to its hyperosmotic properties. Please refer to the latest approved local package insert for Zaltrap® for more information on the correct administration.

 
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg/, and follow the procedures below to access the MOH Alert system.

Step 1: Scroll down to the bottom navigation panel of the HPP web page. Under the Healthcare Professionals section, expand the dropdown option for ‘Healthcare Professional Portal’ and select your profession. You will be redirected to the specific HPP web page to log in.

Step 2: Click on the Restricted Content icon on the left panel of the web page and log in via SingPass.

Step 3: Click on the MOH Alert icon under the ‘Applications’ section.

Step 4: Click on the Drug Alert tab to view the DHCPLs.